Aetna posts a Standard Control Choice formulary addition for Zepbound effective October 1

Aetna has published a formulary update showing Zepbound (tirzepatide) added to its Standard Control Formulary Choice, in the Endocrine and Metabolic, Antiobesity drug class, effective October 1, 2026 ^[1]. Aetna is owned by CVS Health, and its pharmacy benefits are run through CVS Caremark, so this document is the first plan-level confirmation that a change announced months earlier is actually being put into effect ^[1][2].

The change traces back to a CVS Caremark announcement from May 28, 2026, when the company said it would add Zepbound back to its commercial formularies as an additional preferred option starting October 1, 2026 ^[2]. That announcement also said CVS Caremark would remove the new-to-market block on Foundayo (orforglipron), effective June 1, 2026, where plans approve it for coverage ^[2]. Aetna's document confirms a related move: Foundayo is shifting from non-preferred to preferred status on the same October 1 update ^[1].

CVS Caremark said the goal was to expand GLP-1 choices while keeping costs sustainable for plan sponsors, the employers and organizations that pay for coverage ^[2]. Ed DeVaney, president of CVS Caremark, said the company "acted boldly through active engagement and negotiation with our drug manufacturer partners to tackle affordability and access" ^[2]. CVS Caremark also said it expects the changes to continue delivering "double digit savings" for template formulary customers, a trend it says has held for multiple years ^[2].

Importantly, plan sponsors that use CVS Caremark's template formularies can still customize coverage for their own members, so not every employer or plan will necessarily adopt the Zepbound addition ^[2]. The Aetna document itself notes that formulary listings, exclusions, precertification requirements, quantity limits and step therapy rules are all subject to change ^[1]. The same document also lists other coverage shifts effective October 1, including several drugs moving from preferred to non-preferred tiers in unrelated classes, such as Farxiga and Xigduo XR for diabetes and Briviact for seizures ^[1].

Why it matters for patients

For people with Aetna coverage through a plan that adopts this template formulary, the October 1 date is when Zepbound could become available as a covered, preferred option again, if their specific plan follows the CVS Caremark template ^[1][2]. But formulary status alone does not guarantee an easy path to the medication. The Aetna document confirms that exclusions, precertification, quantity limits and step therapy still apply and can change ^[1]. That means some patients may still need prior authorization from a doctor, may face limits on quantity, or may be required to try other treatments first before Zepbound is covered.

Because plan sponsors can customize their formularies, patients cannot assume their individual employer or plan will follow this update automatically ^[2]. Anyone with Aetna coverage would need to check their specific plan documents or member website after October 1 to see whether Zepbound is actually covered for them and under what conditions ^[1].

The same update also affects orforglipron, sold as Foundayo, which is moving to preferred status under this formulary ^[1]. This is separate from tirzepatide (Zepbound) and semaglutide (Ozempic, Wegovy, Rybelsus), and reflects a broader reshuffling of GLP-1 options within this one insurer's coverage rules ^[1][2].

What happens next

The formulary changes described in Aetna's document take effect October 1, 2026 ^[1]. The document notes that the underlying update information is current "as of July 1, 2026" and remains subject to change before that effective date ^[1]. It is not yet known from these sources how many individual plans will adopt the template formulary as written, what specific precertification or step therapy criteria will apply to Zepbound, or how other insurers besides Aetna and CVS Caremark-administered plans are handling coverage for the same period.